A phase II study evaluated maintenance rucaparib in patients with platinum-responsive pancreatic cancer and a pathogenic germline and somatic variant in BRCA1, BRCA2, or PALB2. This evidence concerns the gene BRCA1 and pancreatic neoplasm.